First Wave of Biosimilar Drugs May Save Billions for Patients and Insurers

From Healthline.com
By Ann Pietrangelo 23SEP2016

Biologic drugs offer highly effective medical treatments, but come with a hefty price tag. Creating biosimilar versions may change that…

<Read Full Article>

September 23, 2016 BioFactura In The News

About BioFactura

BioFactura (Frederick MD) develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases.